Catalin Bobirca/LinkedIn
Jun 16, 2026, 14:36
Catalin Bobirca: EHA 2026 Showcases the Future of Hemoglobinopathies Care
Catalin Bobirca, Director of Global Medical Affairs Hemoglobinopathies at Novo Nordisk, shared a post on LinkedIn:
“Back from EHA 2026 and feeling incredibly inspired!
The updates in hemoglobinopathies research highlight just how far we’ve come—and where the future of medicine is heading.
Beyond the data, the highlight of my week was connecting (and reconnecting) with so many dedicated physicians and peers.
Thank you for the insightful discussions and your shared commitment to transforming patient lives.
Let’s stay connected!
One special thanks to the team that made all this possible!”

Stay updated with Hemostasis Today.
-
Nov 17, 2026, 14:10Wolfgang Miesbach: Aspirin vs Anticoagulants – Who Needs More Than Aspirin?
-
Nov 17, 2026, 14:08Chaza Alaji: Soluble Transferrin Receptor – A Key to Uncovering Hidden Iron Deficiency
-
Nov 17, 2026, 14:03Shadi Tabibian: Fibrinogen – From Molecular Structure to Clinical Decision Making
-
Nov 17, 2026, 13:54Gabrielle Sarlon: Breaking the Silence on Menstrual Bleeding During Anticoagulant Therapy
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome
-
Nov 17, 2026, 13:37Abdlemewla Ibrahim: Prasugrel vs Ticagrelor in ACS Patients Undergoing PCI
-
Nov 17, 2026, 13:30Stacy E. Croteau: Oral and Dental Care in Pediatric Patients With Bleeding Disorders
-
Nov 17, 2026, 13:19Efe Saglam: Cannabis Use and Cardiac Conduction
-
Nov 17, 2026, 10:41Elena Petkovic։ Highlights from the ISBT–WHO Plasma Management Workshop